Anavex life sciences to present at the h.c. wainwright 4th annual neuropsychiatry virtual conference

New york, june 20, 2023 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced that christopher u. missling, phd, president and chief executive officer of anavex, will participate in a fireside chat at the h.c. wainwright 4th annual neuropsychiatry virtual conference taking place on june 26, 2023.
AVXL Ratings Summary
AVXL Quant Ranking